Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04176133
Other study ID # 19-004847
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 30, 2019
Est. completion date March 30, 2022

Study information

Verified date May 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers are evaluating the safety and effectiveness of a single administration of entolimod when administered at the same time as the influenza vaccine (flu vaccine).


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date March 30, 2022
Est. primary completion date March 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years and older
Eligibility Inclusion: - Men and women of age 65 years and older at the time of enrollment - Eligible to receive Fluzone High-Dose - Female subjects must be past menopause and not pregnant - No history of anaphylactic reaction to gelatin, neomycin, or other vaccine component - Must not have had the flu vaccine within the past 90 days - Medically stable with no exacerbations or changes in medication regimen for chronic diseases in the past 3 months and no hospitalizations in the past 6 months - Must be able to read/write English in order to provide informed consent and comply with study procedures - Expected to be available for the duration of the study Exclusion: - Receipt of any other vaccines within the past 30 days prior to enrollment - Acute illness within the last 7 days - History of hypersensitivity to the flu vaccine or its components (including gelatin, formaldehyde, octoxinol, thimerosal, and chicken protein). - History of Guillain Barré syndrome (GBS) - History of bleeding disorders - Medical contraindication to treatment with vaccine as indicated by a history of autoimmune disease, immune deficiency, or hypersensitivity to other vaccines. - Unstable major cardiovascular, renal, endocrine, immunological or hepatic disorder - Systolic blood pressure (SBP) < 110 mmHg or orthostatic hypotension [>20 mmHg fall in SBP or >10 mmHg fall in diastolic blood pressure (DBP) with standing] at the time of screening. - Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) (within 14 days prior to entolimod administration). Note: Subjects with localized fungal infections of skin or nails are eligible. - Clinical signs of febrile illness (temperature >99.5oF) - Baseline vital signs with =Grade 2 abnormalities - Significant cardiovascular disease (e.g., myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism, venous thromboembolism) within 6 months prior to study drug administration; symptomatic dysrhythmias or unstable dysrhythmias requiring medical therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart failure; or uncontrolled Grade =3 hypertension (diastolic blood pressure =100 mmHg or systolic blood pressure =160 mmHg) despite antihypertensive therapy. o Significant screening ECG abnormalities, including unstable cardiac arrhythmia requiring medication, atrial fibrillation, 2nd-degree atrioventricular (AV) block type II, 3rd degree AV block, or Grade =2 bradycardia (within 14 days prior to entolimod administration). - Inadequate hepatic function (within 14 days prior to entolimod administration): - Serum alanine aminotransferase (ALT) =3 × upper limit of normal (ULN) (Grade =1). - Serum aspartate aminotransferase (AST) =3 × ULN (Grade =1) - Serum alkaline phosphatase (ALP) =5 × ULN (Grade =2) - Serum bilirubin =1.5 × ULN (Grade =1) - Positive antiviral serology: - Positive hepatitis C virus (HCV) antibody or positive HCV ribonucleic acid (RNA) by quantitative PCR. - Positive hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc) antibody or undetectable hepatitis B (HBV) deoxyribonucleic acid (DNA) by quantitative polymerase chain reaction (PCR) testing. - Positive human immunodeficiency virus (HIV) antibody. - Use of medication that might interact with the flu vaccine including (but not limited to) specifically: aminopyrine, phenytoin sodium, theophylline, and warfarin sodium. - Any ongoing treatment with immunosuppressive or immune-stimulant therapy - Ongoing use of systemic corticosteroids. - Blood or blood products given within the three months prior to vaccination and two months after vaccination - Current and/or expected receipt of chemotherapy, radiation therapy or any other cytotoxic or immunosuppressive therapy [i.e. more than 10 mg of prednisone given daily or on alternative days for 2 weeks or more in the past 3 months] - Receipt of another investigational pharmaceutical product within 60 days of treatment - Diagnosis of Parkinson's Disease, previous stroke, or significant cognitive impairment (defined as MMSE <20) - Other concerns that in the opinion of the PI would preclude a subject from participating in study procedures or from completing the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Entolimod
Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
Placebo
Intramuscular (IM) single dose administration, no active ingredient. A matching placebo is provided as a sterile, clear, colorless to slightly yellow liquid for IM injection in prefilled vials that are identical in appearance to the vials containing active drug.
Influenza vaccine
Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Robert J. Pignolo Genome Protection, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Anti- A/H1N1 Antibody Titer Change of the anti- A/H1N1 influenza virus strains serum circulating antibodies (as assessed using hemagglutination inhibition (HAI) assay) levels from baseline to 1 month. Baseline, 1 month
Primary Change in Anti-A/H3N2 Antibody Titer Change of the anti-A/H3N2 influenza virus strains serum circulating antibodies (as assessed using hemagglutination inhibition (HAI) assay) levels from baseline to 1 month. Baseline, 1 month
Primary Change in Anti-B Antibody Titer Change of the anti-B influenza virus strains serum circulating antibodies (as assessed using hemagglutination inhibition (HAI) assay) levels from baseline to 1 month.. Baseline, 1 month
Primary Adverse Events The number of adverse events (AEs) related to dose limiting toxicities (DLTs); laboratory abnormalities; oxygen saturation and vital sign changes, and adverse electrocardiogram (ECG) findings for 1 year 1 year
Secondary Time of Onset for Upper-respiratory Infections Subject self-reporting of the number of days to develop an upper-respiratory infection 1 year
Secondary Upper Respiratory Infections The total number of subjects to self-report an upper-respiratory infection 1 year
Secondary Change in Frailty Change in self-reported 5 items frail scale. Frail scale scores range from 0-5, 1 point for each component, 0 = best 5 = worst (robust=0 points; pre-frail=0-1 points; frail 3-5 points) baseline, 2 months
Secondary Change in 6-minute Walk Test Distance a subject is able to walk over 6 minutes over a hard flat surface baseline, 2 months
Secondary Change in Grip Strength Measured by a grip dynamometer as reported in units of pounds. baseline, 2 months
Secondary Change in Body Mass Index (BMI) Subject's BMI calculated as weight in kilograms divided by height in meters squared. Uses measurements of height and weight obtained during study (with appropriate metric conversions) baseline, 2 months
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1

External Links